- Home
- IINN vs SNTI Comparison
IINN vs SNTI Comparison
Compare IINN & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IINN
- SNTI
- Stock Information
- Founded
- IINN 2018
- SNTI 2016
- Country
- IINN Israel
- SNTI United States
- Employees
- IINN N/A
- SNTI N/A
- Industry
- IINN Medical/Dental Instruments
- SNTI Biotechnology: Pharmaceutical Preparations
- Sector
- IINN Health Care
- SNTI Health Care
- Exchange
- IINN Nasdaq
- SNTI Nasdaq
- Market Cap
- IINN 40.4M
- SNTI 39.6M
- IPO Year
- IINN 2021
- SNTI N/A
- Fundamental
- Price
- IINN $1.17
- SNTI $1.72
- Analyst Decision
- IINN Strong Buy
- SNTI Strong Buy
- Analyst Count
- IINN 1
- SNTI 2
- Target Price
- IINN $2.00
- SNTI $8.50
- AVG Volume (30 Days)
- IINN 367.7K
- SNTI 138.9K
- Earning Date
- IINN 10-01-2025
- SNTI 11-13-2025
- Dividend Yield
- IINN N/A
- SNTI N/A
- EPS Growth
- IINN N/A
- SNTI N/A
- EPS
- IINN N/A
- SNTI N/A
- Revenue
- IINN $289,000.00
- SNTI N/A
- Revenue This Year
- IINN N/A
- SNTI N/A
- Revenue Next Year
- IINN $2,050.00
- SNTI $150.00
- P/E Ratio
- IINN N/A
- SNTI N/A
- Revenue Growth
- IINN N/A
- SNTI N/A
- 52 Week Low
- IINN $0.40
- SNTI $1.26
- 52 Week High
- IINN $1.65
- SNTI $16.94
- Technical
- Relative Strength Index (RSI)
- IINN 42.39
- SNTI 69.62
- Support Level
- IINN $1.16
- SNTI $1.36
- Resistance Level
- IINN $1.23
- SNTI $1.43
- Average True Range (ATR)
- IINN 0.06
- SNTI 0.09
- MACD
- IINN -0.01
- SNTI 0.04
- Stochastic Oscillator
- IINN 0.00
- SNTI 79.55
About IINN Inspira Technologies Oxy B.H.N. Ltd.
Inspira Technologies Oxy BHN Ltd is a specialty medical device company engaged in the research, development, manufacture, and marketing of proprietary respiratory support technology that is intended to provide an alternative to invasive mechanical ventilation (MV), which is the standard of care today for the treatment of respiratory failure. The respiratory care devices market is segmented geographically into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.